FDA grants priority review to Genentech's Gazyva for kidney disease
Tweet Send to a Friend
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), said the U.S. Food and Drug Administration has ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


